InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
MTBC is a healthcare information technology company that provides a fully integrat...
MTBC is a healthcare information technology com...
InnaMed is developing a comprehensive care management platform. Our team is develo...
InnaMed is developing a comprehensive care mana...
For more than 40 years, Option Care has been shaping the home infusion services in...
For more than 40 years, Option Care has been sh...
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...
G1 Therapeutics, Inc., is a clinical-stage biop...
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, de...
Entasis is a clinical-stage biopharmaceutical c...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a significant return for its shareho...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
Caladrius is a clinical-stage biopharmaceutical company committed to the developme...
Caladrius is a clinical-stage biopharmaceutical...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering,...
Gossamer Bio is a clinical-stage biopharmaceuti...
Join the National Investor Network and get the latest information with your interests in mind.